Back to top
more

Novartis (NVS)

(Real Time Quote from BATS)

$110.81 USD

110.81
489,003

+0.49 (0.44%)

Updated Jul 29, 2024 01:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 26% (185 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Incyte (INCY) Gets FDA Nod for Label Expansion of Pemazyre

by Zacks Equity Research

Incyte (INCY) obtains FDA approval for Pemazyre for a second indication - the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms with FGFR1 rearrangement.

The Zacks Analyst Blog Highlights Novartis, J&J, AbbVie, Merck and Pfizer

by Zacks Equity Research

Novartis, J&J, AbbVie, Merck and Pfizer are part of The Zacks top Analyst Blog.

Alnylam (ALNY) Up More Than 60% in Past 3 Months: Here's Why

by Zacks Equity Research

Alnylam's (ALNY) portfolio of approved drugs is witnessing a strong uptake while its pipeline is progressing well. The recent FDA approval of Amvuttra for a rare disease is a positive.

Puma Biotech's (PBYI) Nerlynx Aids Top Line, Overdependence a Woe

by Zacks Equity Research

Puma Biotech (PBYI) has only one marketed product in its portfolio, Nerlynx, for HER-2 positive breast cancer patients. It continues to evaluate Nerlynx in other types of cancer and indications.

Kinjel Shah headshot

Pharma Stock Roundup: NVS to Spin Off Sandoz; JNJ, MRK, ABBV's FDA Updates

by Kinjel Shah

Novartis (NVS) plans to spin off its generics division, Sandoz. The FDA approves J&J (JNJ) and AbbVie's (ABBV) Imbruvica for pediatric indication cGVHD.

Novartis (NVS) Plans to Spin Off Generics Business Sandoz

by Zacks Equity Research

Novartis (NVS) is set to spin off Sandoz into a new publicly traded standalone company to focus better on its core pharmaceutical business.

Aerie (AERI) to be Acquired by Alcon for $770M, Shares Up

by Zacks Equity Research

Aerie (AERI) enters into an agreement with Alcon to be acquired for $770 million. Shares gain.

Kinjel Shah headshot

Pharma Stock Roundup: End of SNY's Amcenestrant Development, FDA Updates for AZN, GSK

by Kinjel Shah

Sanofi (SNY) ends the development of breast cancer candidate, amcenestrant. Novartis' (NVS) lung cancer candidate, canakinumab fails a phase III study. FDA grants priority review to AstraZeneca (AZN) and Merck's (MRK) Lynparza sNDA.

Novartis (NVS) NSCLC Study Fails to Meet Primary Endpoint

by Zacks Equity Research

Novartis (NVS) suffers a setback as canakinumab fails to meet the primary goal in yet another study for lung cancer.

Bausch (BHC) to Appeal Regarding Xifaxan Patent Decision

by Zacks Equity Research

Bausch (BHC) will appeal to the U.S. Court of Appeals for the Federal Circuit regarding the patent decision for one of its key drugs Xifaxan.

Ionis (IONS) Q2 Earnings & Sales Miss Estimates, Stock Down

by Zacks Equity Research

Ionis (IONS) incurs a wider-than-expected loss in Q2. Its sales also miss estimates. Stock moves down in response to the results.

Incyte's (INCY) Earnings and Revenues Surpass Estimates in Q2

by Zacks Equity Research

Incyte's (INCY) earnings and revenues trump estimates in the second quarter of 2022. The company raises the bottom end of full-year Jakafi's net product revenue guidance.

Emergent's (EBS) Q2 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Emergent's (EBS) second-quarter 2022 earnings and revenues miss estimates. EBS issues fresh guidance for its CDMO services.

Drug, Biotech Stocks' Q2 Earnings on Aug 2: GILD, INCY & More

by Zacks Equity Research

Let's check out how the four pharma/drug/biotech companies are placed before the quarterly earnings release on Aug 2.

The Zacks Analyst Blog Highlights Novartis, Duke Energy, Boston Scientific, Norfolk Southern and Cadence Design Systems

by Zacks Equity Research

Novartis, Duke Energy, Boston Scientific, Norfolk Southern and Cadence Design Systems are part of Zacks top Analyst Blog.

Sheraz Mian headshot

Top Analyst Reports for Novartis, Duke Energy & Boston Scientific

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Novartis AG (NVS), Duke Energy Corporation (DUK), and Boston Scientific Corporation (BSX).

Alnylam's (ALNY) Earnings and Revenues Lag Estimates in Q2

by Zacks Equity Research

Alnylam's (ALNY) earnings and sales fall shy of estimates in the second quarter of 2022. The company maintains its revenue guidance for 2022.

Incyte (INCY) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Incyte's (INCY) top line is likely to have been driven by sales of its lead drug, Jakafi, in the second quarter.

The Zacks Analyst Blog Highlights J&J, Novartis, GSK, Merck and AbbVie

by Zacks Equity Research

J&J, Novartis, GSK, Merck and AbbVie are included in this Analyst Blog.

Kinjel Shah headshot

Pharma Stock Roundup: JNJ, NVS Q2 Earnings, GSK Consumer Unit Spin-Off

by Kinjel Shah

J&J (JNJ) and Novartis (NVS) report Q2 earnings. GSK completes separation of its Consumer Healthcare (CHC) segment.

Olema (OLMA) Up on FDA Fast Track Tag for Breast Cancer Drug

by Zacks Equity Research

The FDA bestows a Fast Track designation to Olema's (OLMA) novel pipeline candidate, OP-1250, for the treatment of ER+/HER2- metastatic breast cancer. Stock up.

Ionis (IONS) Partner Wraps Up Cardiovascular Study Enrollment

by Zacks Equity Research

Ionis' (IONS) partner, Novartis completes enrolling patients in a phase III study on pelacarsen for treating cardiovascular disease due to elevated Lp(a) levels. Data from this study is expected in 2025.

Company News for Jul 20, 2022

by Zacks Equity Research

Companies in The News Are: BA, NVS, TFC, IBM

Incyte (INCY) Gets FDA Nod for Label Expansion of Opzelura

by Zacks Equity Research

Incyte (INCY) Opzelura cream 1.5% gets FDA approval for another indication - nonsegmental vitiligo in adult and pediatric patients 12 years of age and older.

Novartis (NVS) Q2 Earnings Beat, Revenues Miss Estimates

by Zacks Equity Research

Novartis (NVS) reports mixed results in the second quarter, as key brands maintain momentum but generic competition remains a drag.